Welcome to our dedicated page for BeiGene, Ltd. American Depositary Shares news (Ticker: BGNE), a resource for investors and traders seeking the latest updates and insights on BeiGene, Ltd. American Depositary Shares stock.
BeiGene, Ltd. (NASDAQ: BGNE) is a global biotechnology company specializing in the development and commercialization of innovative cancer treatments. With a robust portfolio focused on molecularly targeted and immuno-oncology drugs, BeiGene addresses crucial oncology targets such as Bruton's tyrosine kinase (BTK) and the immune checkpoint protein PD-1. The company’s notable products include tislelizumab, a PD-1 inhibitor, and zanubrutinib, a BTK inhibitor, which have shown promising results in treating various cancers. BeiGene’s latest achievements include FDA and European regulatory approvals, significant clinical trial successes, and partnerships aimed at expanding the reach of their therapies globally. The company operates across major markets, including China, the United States, and internationally, striving to make high-quality cancer treatments more accessible. BeiGene’s commitment to advancing global health equity is evident in its innovative drug pipeline and strategic collaborations.
News
Rhea-AI Summary
BeiGene, a global biotechnology company (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), announced positive results from ongoing studies and trials at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition. The data showcases the potential of BRUKINSA as a best-in-class BTK inhibitor and promising clinical advances across their pipeline, including the BCL2 inhibitor sonrotoclax and BTK degrader BGB‑16673.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.03%
Tags
-
Rhea-AI Summary
BeiGene (BGNE) acquires an exclusive global license to an Investigational New Drug (IND) application-ready oral cyclin-dependent kinase 2 (CDK2) inhibitor from Ensem Therapeutics, Inc. The agreement involves an upfront payment and potential additional payments of up to $1.33 billion, along with tiered royalties. This partnership strengthens BeiGene's early development pipeline in breast cancer and other solid tumors, complementing their internally discovered Phase 1 CDK4 inhibitor. Ensem will work with BeiGene to bring this molecule into the clinic in the near future, aiming to transform the therapeutic landscape for cancer patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.57%
Tags
-
Rhea-AI Summary
BeiGene, Ltd. (Nasdaq: BGNE; HKEX: 06160; SSE: 688235) announced that the European Commission granted marketing authorization for BRUKINSA® (zanubrutinib) in combination with obinutuzumab for the treatment of adult patients with relapsed or refractory follicular lymphoma. This is the fourth indication in the EU for BRUKINSA, making it the first and only BTK inhibitor approved for follicular lymphoma in the European Union, with the broadest label of any medicine in its class globally. The approval was based on results from the ROSEWOOD trial, where BRUKINSA plus obinutuzumab achieved a higher overall response rate compared to obinutuzumab alone.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.21%
Tags
Rhea-AI Summary
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235) reported $781 million in total revenue and $595 million in global product sales for the third quarter of 2023, reflecting a 102% and 70% increase from the prior-year period, respectively. Key highlights include the approval of TEVIMBRA in the EU for 2L esophageal squamous cell carcinoma (ESCC) and the acceptance for review of a Biologics License Application (BLA) for tislelizumab as a first-line treatment for patients with ESCC in the U.S.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.04%
Tags
-
Rhea-AI Summary
BeiGene, Ltd. (BGNE) to participate in Jefferies London Healthcare Conference on November 15th, 2023, offering a fireside chat at 2:00 pm GMT. Investors can access the live webcast on the company's website. Archived replays available for 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.27%
Tags
-
Rhea-AI Summary
BeiGene's BRUKINSA receives final draft guidance recommendation from NICE for the treatment of CLL patients
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.12%
Tags
Rhea-AI Summary
BeiGene's Phase 3 RATIONALE 315 study shows positive results for tislelizumab in patients with resectable NSCLC
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.34%
Tags
-
Rhea-AI Summary
BeiGene announces positive results from Phase 3 RATIONALE 305 trial of tislelizumab plus chemotherapy in gastric cancer patients
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.34%
Tags
-
Rhea-AI Summary
BeiGene presents promising data on tislelizumab at ESMO Congress 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.71%
Tags
Rhea-AI Summary
CHMP recommends approval for BRUKINSA plus obinutuzumab as a treatment for adult patients who have received at least two prior lines of therapy
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.45%
Tags
FAQ
What is the current stock price of BeiGene, Ltd. American Depositary Shares (BGNE)?
The current stock price of BeiGene, Ltd. American Depositary Shares (BGNE) is $189.23 as of November 15, 2024.
What is the market cap of BeiGene, Ltd. American Depositary Shares (BGNE)?
The market cap of BeiGene, Ltd. American Depositary Shares (BGNE) is approximately 19.9B.
What type of company is BeiGene, Ltd.?
BeiGene, Ltd. is a global biotechnology company focused on developing and commercializing innovative cancer treatments.
What are some of BeiGene’s notable products?
Some of BeiGene’s notable products include tislelizumab, a PD-1 inhibitor, and zanubrutinib, a BTK inhibitor.
What markets does BeiGene operate in?
BeiGene operates in major markets including China, the United States, and internationally.
What recent achievements has BeiGene accomplished?
Recent achievements include the FDA and European regulatory approvals for its cancer treatments, significant clinical trial successes, and strategic partnerships.
What are BeiGene’s primary focus areas in oncology?
BeiGene focuses on molecularly targeted and immuno-oncology drugs, addressing targets like BTK and the immune checkpoint protein PD-1.
How does BeiGene contribute to global health equity?
BeiGene contributes to global health equity by developing innovative cancer treatments and forming strategic collaborations to make these therapies more accessible.
What are the financial highlights for BeiGene's latest quarter?
For the latest quarter, BeiGene reported total revenues of $752 million with significant growth in BRUKINSA product sales in the U.S. and Europe.
What is the significance of BeiGene's drug zanubrutinib?
Zanubrutinib is a BTK inhibitor that has shown promising results in treating various cancers, leading to increased market share and regulatory approvals.
What strategic initiatives is BeiGene currently pursuing?
BeiGene is focusing on expanding its global presence, advancing its innovative drug pipeline, and enhancing collaborations to broaden the accessibility of its cancer treatments.
What impact has BeiGene made on cancer treatment accessibility?
BeiGene has made significant strides in making high-quality cancer treatments more accessible globally through innovative drug development and strategic partnerships.
BeiGene, Ltd. American Depositary Shares
Nasdaq:BGNE
BGNE Rankings
BGNE Stock Data
19.88B
1.25B
19.48%
49.53%
1.42%
Biotechnology
Pharmaceutical Preparations
United States of America
GRAND CAYMAN